Abion에이비온
203400 · KOSDAQ · ₩203400 · 에이비온
- Market cap
- ₩61B
- Enterprise value
- ₩53B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −53.6%
- Net margin
- −3,017.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−85.0% from the high
₩2,850Today: ₩3,380 – ₩3,380₩22,550
Returns
- 1W0.0%
- 1M0.0%
- 3M−12.3%
- 6M−74.2%
- YTD−78.4%
- 1Y−74.6%
- Volume today
- —
- Traded today
- —
- Listed shares
- 18,020,260
- EPS (12 months)
- −₩1,573
- Earnings yield −46.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Abion stock overview
Abion (에이비온, KRX: 203400) is listed on KOSDAQ, in the Biotech & Pharma sector. AB Pharmaceutical-style biotech listed on KOSDAQ that develops companion-diagnostic-based cancer drugs and drug candidates, selecting patients through biomarkers. Its shares closed at ₩3,380 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩61B.
Key facts
- Market cap
- ₩61B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- AB Pharmaceutical-style biotech listed on KOSDAQ that develops companion-diagnostic-based cancer drugs and drug candidates, selecting patients through biomarkers.
Quick answers about Abion
- What does Abion do?
- AB Pharmaceutical-style biotech listed on KOSDAQ that develops companion-diagnostic-based cancer drugs and drug candidates, selecting patients through biomarkers. Its main pipeline includes Vabametkib (ABN401), a targeted therapy for non-small cell lung cancer, ABN501 targeting Claudin3, ABN202 antibody-cytokine fusion platform, and ABN101, an interferon-beta based broad-spectrum antiviral. Most recent revenue comes from government-commissioned research services, with office rental income making up the rest; the company plans to generate revenue mainly through technology licensing to pharmaceutical companies and operates in South Korea.
- What is the market cap of Abion?
- The market capitalisation of Abion was ₩61B at the close on Oct 27, 2026.
- Who are the largest shareholders of Abion?
- According to the latest official filings, the largest reported holders are Telcon RF Pharmaceutical (18.78%, as of Oct 13, 2026); Shin Young-gi (2.35%, as of Oct 8, 2026); Choi Young-ho (1.62%, as of Jul 10, 2025).
- When is the next earnings report from Abion?
- Korean companies rarely announce results dates in advance. Based on when Abion filed the same report in past years, its next 3q results is expected between Oct 31, 2026 and Nov 14, 2026.
- Does the National Pension Service own Abion?
- Yes. The National Pension Service held 0.98% of Abion shares as of Dec 31, 2021.
Company profile
AB Pharmaceutical-style biotech listed on KOSDAQ that develops companion-diagnostic-based cancer drugs and drug candidates, selecting patients through biomarkers. Its main pipeline includes Vabametkib (ABN401), a targeted therapy for non-small cell lung cancer, ABN501 targeting Claudin3, ABN202 antibody-cytokine fusion platform, and ABN101, an interferon-beta based broad-spectrum antiviral. Most recent revenue comes from government-commissioned research services, with office rental income making up the rest; the company plans to generate revenue mainly through technology licensing to pharmaceutical companies and operates in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 에이비온
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 신영기
- Founded
- Apr 2007
- Listed
- Sep 2021
- Listed shares
- 18,020,260
- Fiscal year ends
- Month 12
- Website
- www.abionbio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Other Market Notice (Submission of Improvement Plan)Oct 23, 2026
- Insider shareholding reportOct 13, 2026
- Insider shareholding reportOct 8, 2026
- Insider shareholding reportOct 8, 2026
- Insider shareholding reportOct 8, 2026
Titles in Korean until English translations are added.
Also known as: Abion / 에이비온 / 203400 / KRX:203400
Source: KRX statistical information